Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014

Abstract Effective treatment options for adults with therapy-related AML continues to be an area of unmet need. Genetic and molecular changes within these leukemias confer resitance to standard chemotherapy regimens. Emerging develpmental therapeutics in this area has focused on several approaches....

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2015-06, Vol.15, p.S91-S93
Main Author: Feldman, Eric J
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Hematology, Oncology and Palliative Medicine
Humans
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - etiology
New treatment of secondary AML
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c411t-31528e50f2a6b3d6f161deb5587303a355029ef3dd50f18ab87951257f03aa5c3
cites cdi_FETCH-LOGICAL-c411t-31528e50f2a6b3d6f161deb5587303a355029ef3dd50f18ab87951257f03aa5c3
container_end_page S93
container_issue
container_start_page S91
container_title Clinical lymphoma, myeloma and leukemia
container_volume 15
creator Feldman, Eric J
description Abstract Effective treatment options for adults with therapy-related AML continues to be an area of unmet need. Genetic and molecular changes within these leukemias confer resitance to standard chemotherapy regimens. Emerging develpmental therapeutics in this area has focused on several approaches. These include; novel delivery of chemotherapy as well as newer DNA-damaging agents delivered through antibody-drug conjugates, increased use of hypomethylating agents, and molecularly-directed small molecules against specific mutations commonly occuring in secondary AML. Results of this efforts are encouraging, but to date, no clear improvements have been demonstrated in this most difficult to treat population.
doi_str_mv 10.1016/j.clml.2015.02.031
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1706576892</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S2152265015000750</els_id><sourcerecordid>1706576892</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-31528e50f2a6b3d6f161deb5587303a355029ef3dd50f18ab87951257f03aa5c3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUha0K1D94ARZVlmwS7rVrJ6kqpGrUFqQBJChry2PfCE-dyWAnlebt62imXbBgZcs-51z7O4x9QKgQUH1aVzb0oeKAsgJegcAjdspR8pIr1b553Us4YWcprQFqAGyP2QlXvK15U5-yxffhiULx8Iei2dI0epuKboiHg135k4IZyRU3dhqp-LajMHhXLGl6pN6bqyIPv3zH3nYmJHp_WM_Z77vbh8WXcvnj_uviZlnaS8SxFPk1DUnouFEr4VSHCh2tpGxqAcIIKYG31AnnsgYbs2rqViKXdZdvjbTinH3c527j8HeiNOreJ0shmA0NU9JYg5K1alqepXwvtXFIKVKnt9H3Ju40gp7h6bWe4ekZngauM7xsujjkT6ue3KvlhVYWXO8FlH_55CnqZD1tLDkfyY7aDf7_-Z__sdvgN96a8Eg7SuthipvMT6NO2aB_zfXN7aGEXJ0E8Qxdp5J2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1706576892</pqid></control><display><type>article</type><title>Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Feldman, Eric J</creator><creatorcontrib>Feldman, Eric J</creatorcontrib><description>Abstract Effective treatment options for adults with therapy-related AML continues to be an area of unmet need. Genetic and molecular changes within these leukemias confer resitance to standard chemotherapy regimens. Emerging develpmental therapeutics in this area has focused on several approaches. These include; novel delivery of chemotherapy as well as newer DNA-damaging agents delivered through antibody-drug conjugates, increased use of hypomethylating agents, and molecularly-directed small molecules against specific mutations commonly occuring in secondary AML. Results of this efforts are encouraging, but to date, no clear improvements have been demonstrated in this most difficult to treat population.</description><identifier>ISSN: 2152-2650</identifier><identifier>EISSN: 2152-2669</identifier><identifier>DOI: 10.1016/j.clml.2015.02.031</identifier><identifier>PMID: 26297287</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Hematology, Oncology and Palliative Medicine ; Humans ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - etiology ; New treatment of secondary AML ; Treatment Outcome</subject><ispartof>Clinical lymphoma, myeloma and leukemia, 2015-06, Vol.15, p.S91-S93</ispartof><rights>Elsevier Inc.</rights><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-31528e50f2a6b3d6f161deb5587303a355029ef3dd50f18ab87951257f03aa5c3</citedby><cites>FETCH-LOGICAL-c411t-31528e50f2a6b3d6f161deb5587303a355029ef3dd50f18ab87951257f03aa5c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26297287$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Feldman, Eric J</creatorcontrib><title>Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014</title><title>Clinical lymphoma, myeloma and leukemia</title><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><description>Abstract Effective treatment options for adults with therapy-related AML continues to be an area of unmet need. Genetic and molecular changes within these leukemias confer resitance to standard chemotherapy regimens. Emerging develpmental therapeutics in this area has focused on several approaches. These include; novel delivery of chemotherapy as well as newer DNA-damaging agents delivered through antibody-drug conjugates, increased use of hypomethylating agents, and molecularly-directed small molecules against specific mutations commonly occuring in secondary AML. Results of this efforts are encouraging, but to date, no clear improvements have been demonstrated in this most difficult to treat population.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - etiology</subject><subject>New treatment of secondary AML</subject><subject>Treatment Outcome</subject><issn>2152-2650</issn><issn>2152-2669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAUha0K1D94ARZVlmwS7rVrJ6kqpGrUFqQBJChry2PfCE-dyWAnlebt62imXbBgZcs-51z7O4x9QKgQUH1aVzb0oeKAsgJegcAjdspR8pIr1b553Us4YWcprQFqAGyP2QlXvK15U5-yxffhiULx8Iei2dI0epuKboiHg135k4IZyRU3dhqp-LajMHhXLGl6pN6bqyIPv3zH3nYmJHp_WM_Z77vbh8WXcvnj_uviZlnaS8SxFPk1DUnouFEr4VSHCh2tpGxqAcIIKYG31AnnsgYbs2rqViKXdZdvjbTinH3c527j8HeiNOreJ0shmA0NU9JYg5K1alqepXwvtXFIKVKnt9H3Ju40gp7h6bWe4ekZngauM7xsujjkT6ue3KvlhVYWXO8FlH_55CnqZD1tLDkfyY7aDf7_-Z__sdvgN96a8Eg7SuthipvMT6NO2aB_zfXN7aGEXJ0E8Qxdp5J2</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Feldman, Eric J</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150601</creationdate><title>Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014</title><author>Feldman, Eric J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-31528e50f2a6b3d6f161deb5587303a355029ef3dd50f18ab87951257f03aa5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - etiology</topic><topic>New treatment of secondary AML</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Feldman, Eric J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Feldman, Eric J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014</atitle><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>15</volume><spage>S91</spage><epage>S93</epage><pages>S91-S93</pages><issn>2152-2650</issn><eissn>2152-2669</eissn><abstract>Abstract Effective treatment options for adults with therapy-related AML continues to be an area of unmet need. Genetic and molecular changes within these leukemias confer resitance to standard chemotherapy regimens. Emerging develpmental therapeutics in this area has focused on several approaches. These include; novel delivery of chemotherapy as well as newer DNA-damaging agents delivered through antibody-drug conjugates, increased use of hypomethylating agents, and molecularly-directed small molecules against specific mutations commonly occuring in secondary AML. Results of this efforts are encouraging, but to date, no clear improvements have been demonstrated in this most difficult to treat population.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26297287</pmid><doi>10.1016/j.clml.2015.02.031</doi></addata></record>
fulltext fulltext
identifier ISSN: 2152-2650
ispartof Clinical lymphoma, myeloma and leukemia, 2015-06, Vol.15, p.S91-S93
issn 2152-2650
2152-2669
language eng
recordid cdi_proquest_miscellaneous_1706576892
source Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)
subjects Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Hematology, Oncology and Palliative Medicine
Humans
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - etiology
New treatment of secondary AML
Treatment Outcome
title Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T09%3A53%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20Therapeutics%20for%20Therapy-Related%20Acute%20Myeloid%20Leukemia:%202014&rft.jtitle=Clinical%20lymphoma,%20myeloma%20and%20leukemia&rft.au=Feldman,%20Eric%20J&rft.date=2015-06-01&rft.volume=15&rft.spage=S91&rft.epage=S93&rft.pages=S91-S93&rft.issn=2152-2650&rft.eissn=2152-2669&rft_id=info:doi/10.1016/j.clml.2015.02.031&rft_dat=%3Cproquest_cross%3E1706576892%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c411t-31528e50f2a6b3d6f161deb5587303a355029ef3dd50f18ab87951257f03aa5c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1706576892&rft_id=info:pmid/26297287&rfr_iscdi=true